CLINICAL TRIAL: VX-770 IN CYSTIC FIBROSIS SUBJECTS WITH GENOTYPE 551D

临床试验：VX-770 在基因型 551D 囊性纤维化受试者中的应用

• 批准号: 7718952
• 负责人: Steven David Freedman
• 金额: $ 0.02万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718952
• 关键词: Chloride Channels; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dose; Funding; Genotype; Grant; Institution; Investigational Drugs; Nose; Proteins; Protocols documentation; Purpose; Research; Research Personnel; Resources; Screening procedure; Source; Testing; United States National Institutes of Health; VX-770; Visit; day; restoration

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this protocol is to perform Nasal Transepithelial Potential Difference (NPD) testing to assess the effects of an investigational drug (VX-770) on the restoration of the cystic fibrosis gene product, a chloride channel referred to as CFTR. NPD will be performed at the screening visit and days 1 and 14 pre-dose of VX-770 and post-washout days 1 and 14 and then again on day 28, per the sponsor protocol.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该协议的目的是进行鼻跨上皮电位差 (NPD) 测试，以评估研究药物 (VX-770) 对囊性纤维化基因产物（称为 CFTR 的氯离子通道）恢复的影响。 根据申办者方案，NPD 将在筛选访视以及 VX-770 给药前第 1 天和第 14 天以及清洗后第 1 天和 14 天以及第 28 天再次进行。